Prostate cancer antigen 3 (PCA3) scoring, based on urinary PCA3:PSA mRNA ratios, might improve estimation of prostate cancer risk, thereby reducing the need for prostate biopsies. In a validation trial, a PCA3 score >60 had a positive predictive value of 80% and a PCA3 score <20 had a negative predictive value of 88% in men undergoing initial and repeat biopsies, respectively; addition of PCA3 score to the PCPT risk calculator significantly improved the classification of any prostate cancer (P <0.001 in both groups), as well as high-grade cancers in men undergoing repeat biopsy (P ≤0.003).
References
Wei, J. T. et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer. J. Clin. Oncol. 10.1200/JCO.2013.52.8505
Rights and permissions
About this article
Cite this article
PCA3 scoring could improve prostate cancer risk estimation. Nat Rev Clin Oncol 12, 2 (2015). https://doi.org/10.1038/nrclinonc.2014.209
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.209